Oxaliplatin can cause hypersensitivity-mediated immune thrombocytopenia, placing patients
at risk for spontaneous bleeding.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Colorectal CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.J Clin Oncol. 2009; 27: 3109-3116
- Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.J Clin Oncol. 2000; 18: 2938-2947
- Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.Cancer. 2013; 119: 438-444
- Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study.Ann Oncol. 1998; 9: 105-108
- OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.J Clin Oncol. 2006; 24: 394-400
- Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.J Clin Oncol. 2009; 27: 5727-5733
- Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX.Oncology. 2010; 79: 136-143
- Oxaliplatin immune-induced syndrome occurs with cumulative administration and rechallenge: single institution series and systematic review study.Clin Colorectal Cancer. 2016; 15: 213-221
- Platinum compounds: a hope for future cancer chemotherapy.Anticancer Agents Med Chem. 2013; 13: 296-306
- Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.J Clin Oncol. 2007; 25: 1539-1544
- Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.J Clin Oncol. 2008; 26: 2013-2019
- Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.N Engl J Med. 2004; 350: 2343-2351
- Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions.J Formos Med Assoc. 2010; 109: 362-368
- Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review.Oncology. 2009; 76: 231-238
- Allergic reactions to oxaliplatin in a single institute in Japan.Jpn J Clin Oncol. 2009; 39: 616-620
- Hypersensitivity reactions to oxaliplatin: experience in a single institute.Ann Oncol. 2006; 17: 259-261
- Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer.Int J Med Sci. 2011; 8: 210-215
- Hypersensitivity reactions to oxaliplatin: incidence and management.Oncology (Williston Park). 2004; 18 (discussion 1676, 1680, 1683-4): 1671-1675
- Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan.Int J Clin Oncol. 2009; 14: 397-401
- Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.Eur J Cancer. 2005; 41: 2262-2267
- Oxaliplatin-related thrombocytopenia.Ann Oncol. 2012; 23: 1937-1942
- Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.J Clin Oncol. 2010; 28: 2549-2555
- Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury.Clin Colorectal Cancer. 2009; 8: 225-230
- Oxaliplatin-induced immune pancytopenia.Transfusion. 2005; 45: 704-708
- Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin.Am J Hematol. 2006; 81: 193-198
- Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature.J Hematol Oncol. 2010; 3: 12
- Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review.J Oncol Pharm Pract. 2015; 21: 148-156
- A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin.Clin Exp Nephrol. 2012; 16: 490-494
- Oxaliplatin-mediated autoimmune thrombocytopenia.Clin Colorectal Cancer. 2009; 8: 61-62
- Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma.Blood. 2011; 118: 4808-4816
- Oxaliplatin-induced immune mediated thrombocytopenia.Cancer Chemother Pharmacol. 2008; 62: 925-927
- Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies.Blood. 2018; 131: 1486-1489
- Immune-mediated pancytopenia induced by oxaliplatin: a case report.Transfusion. 2010; 50: 1453-1459
- Acute immune hematological complication of oxaliplatin. A series of 3 cases.Tumori. 2014; 100: e17-e19
- Drug-induced immune thrombocytopenia.Drug Saf. 2004; 27: 1243-1252
- Drug-induced thrombocytopenia: a systematic review of published case reports.Ann Intern Med. 1998; 129: 886-890
- A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia.J Thromb Haemost. 2013; 11: 169-176
- Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management.J Thromb Haemost. 2009; 7: 911-918
- Can drugs cause autoimmune thrombocytopenic purpura?.Semin Hematol. 2000; 37: 229-238
- Clinical pharmacokinetics of oxaliplatin: a critical review.Clin Cancer Res. 2000; 6: 1205-1218
- Drug-induced thrombocytopenia: pathogenesis, evaluation, and management.Hematol Am Soc Hematol Educ Progr. 2009; : 153-158
Article info
Publication history
Published online: July 29, 2020
Accepted:
July 24,
2020
Received in revised form:
June 24,
2020
Received:
April 29,
2020
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
